Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine
Targeted BRAF or MEK inhibitor therapy can restore radioactive iodine uptake and enhance response to subsequent radioactive iodine treatment in patients with advanced, RAI‑resistant thyroid cancer.
In a single‑institution case series of 13 patients with advanced, radioactive iodine‑resistant thyroid cancer, treatment with BRAF and/or MEK inhibitors (dabrafenib, vemurafenib, trametinib or combinations) restored radioactive iodine uptake in 8 of 13 (62%) patients and enabled further iodine therapy. Eight patients received additional I‑131 treatment, and 3 achieved partial responses, with one patient experiencing 88 % tumor shrinkage. AEs were limited to inflammatory reactions that resolved within three months.
These findings offer hope for a rare subset of patients whose thyroid cancer has lost the ability to absorb iodine, potentially improving outcomes and highlighting the need for larger prospective studies to identify patients most likely to benefit and to quantify long‑term benefit.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management